← Patent-cliff monitor small molecule ZURZUVAE ZURANOLONE
Loss of exclusivity August 2037 latest FDA-listed patent expiry
Company Biogen → See this company's full patent-cliff portfolio Drug detail Brand name ZURZUVAE Active ingredient ZURANOLONE Strength 30MG Dosage form CAPSULE Route ORAL Modality Small molecule FDA approval October 2023 Marketing status RX
Listed patents Patent Expires Type 11884696 August 2037 use U-2552 11236121 August 2037 substance 10342810 April 2034 use U-2552 10172871 April 2034 use U-2552 9512165 April 2034 substance, product
Regulatory exclusivity Code Expires NCE October 2028
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.